Teacher Retirement System of Texas Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Teacher Retirement System of Texas cut its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 3.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 637,877 shares of the company's stock after selling 24,920 shares during the period. Teacher Retirement System of Texas owned approximately 0.06% of Teva Pharmaceutical Industries worth $9,804,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the business. FMR LLC raised its position in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after buying an additional 19,242,468 shares in the last quarter. Duquesne Family Office LLC grew its position in Teva Pharmaceutical Industries by 530.1% during the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after acquiring an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Teva Pharmaceutical Industries by 472.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after buying an additional 5,186,592 shares during the period. Assenagon Asset Management S.A. increased its position in Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock valued at $91,973,000 after acquiring an additional 4,824,247 shares during the period. Finally, Marshall Wace LLP raised its position in Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after purchasing an additional 2,410,420 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.55% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently commented on the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Stock Down 0.1%

TEVA traded down $0.03 during midday trading on Monday, hitting $16.99. The company had a trading volume of 1,373,141 shares, compared to its average volume of 12,143,234. The stock's 50 day moving average price is $16.99 and its 200 day moving average price is $17.34. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a market capitalization of $19.48 billion, a price-to-earnings ratio of -14.77, a PEG ratio of 0.87 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same period last year, the business posted $0.48 EPS. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.